Vigonvita Life Sciences Management
Management criteria checks 3/4
Vigonvita Life Sciences' CEO is Guanghui Tian, appointed in Jan 2013, has a tenure of 12.83 years. total yearly compensation is CN¥15.50M, comprised of 4% salary and 96% bonuses, including company stock and options. directly owns 8.54% of the company’s shares, worth HK$388.45M. The average tenure of the management team and the board of directors is 3.3 years and 4.2 years respectively.
Key information
Guanghui Tian
Chief executive officer
CN¥15.5m
Total compensation
| CEO salary percentage | 3.96% |
| CEO tenure | 12.8yrs |
| CEO ownership | 8.5% |
| Management average tenure | 3.3yrs |
| Board average tenure | 4.2yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | CN¥15m | CN¥613k | -CN¥211m |
| Dec 31 2023 | CN¥16m | CN¥609k | CN¥12m |
Compensation vs Market: Guanghui's total compensation ($USD2.18M) is above average for companies of similar size in the Hong Kong market ($USD387.38K).
Compensation vs Earnings: Guanghui's compensation has been consistent with company performance over the past year.
CEO
Guanghui Tian (44 yo)
Dr. Guanghui Tian is Co-Founder of Vigonvita Life Sciences Co. Ltd. He serves as General Manager of Vigonvita Life Sciences Co. Ltd. since June 28, 2020 and serves as its Executive Chairman since June 14,...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 12.8yrs | CN¥15.50m | 8.54% HK$ 388.4m | |
| Deputy GM & Executive Director | 2.4yrs | CN¥709.00k | no data | |
| Founder | no data | no data | 53.85% HK$ 2.4b | |
| Financial Controller | 3.3yrs | no data | no data | |
| Joint Company Secretary | less than a year | no data | no data | |
| Secretary of the Board & Joint Company Secretary | 3.3yrs | no data | no data | |
| Deputy General Manager | 3.5yrs | no data | no data |
Experienced Management: 2630's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 5.4yrs | CN¥15.50m | 8.54% HK$ 388.4m | |
| Deputy GM & Executive Director | 2.4yrs | CN¥709.00k | no data | |
| Independent Non-Executive Director | 2.7yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | 2.7yrs | CN¥100.00k | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Non-Executive Director | 5.4yrs | no data | no data | |
| Chairman of the Supervisory Committee | 4.2yrs | no data | no data | |
| Supervisor | 4.2yrs | no data | no data | |
| Employee’s Representative Supervisor | 4.7yrs | no data | no data |
Experienced Board: 2630's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/15 16:58 |
| End of Day Share Price | 2025/11/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Vigonvita Life Sciences Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.